| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Csaba Szabó | Q106704479 |
| Pal Pacher | Q30347235 | ||
| P2860 | cites work | Pharmacological inhibition of poly(ADP-ribose) polymerase in cardiovascular disorders: future directions | Q80387813 |
| Increased expression of poly(ADP-ribose) polymerase-1 contributes to caspase-independent myocyte cell death during heart failure | Q80579473 | ||
| Activation of the peroxynitrite-poly(adenosine diphosphate-ribose) polymerase pathway during neointima proliferation: a new target to prevent restenosis after endarterectomy | Q83157477 | ||
| Poly(ADP-ribose) polymerase-1-deficient mice are protected from angiotensin II-induced cardiac hypertrophy | Q83189364 | ||
| The parp-1 inhibitor ino-1001 facilitates hemodynamic stabilization without affecting DNA repair in porcine thoracic aortic cross-clamping-induced ischemia/reperfusion | Q83834120 | ||
| Contractile dysfunction in experimental cardiac allograft rejection: role of the poly (ADP-ribose) polymerase pathway | Q83984932 | ||
| Leukocyte-depleted terminal blood cardioplegia provides superior myocardial protective effects in association with myocardium-derived nitric oxide and peroxynitrite production for patients undergoing prolonged aortic crossclamping for more than 120 | Q94334060 | ||
| Molecular characterization of mitochondrial apoptosis-inducing factor | Q22001452 | ||
| Characterization of five human cDNAs with homology to the yeast SIR2 gene: Sir2-like proteins (sirtuins) metabolize NAD and may have protein ADP-ribosyltransferase activity | Q22010164 | ||
| Nitric oxide and peroxynitrite in health and disease | Q24645400 | ||
| Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol | Q24652967 | ||
| Role of nitrosative stress and peroxynitrite in the pathogenesis of diabetic complications. Emerging new therapeutical strategies | Q24656109 | ||
| NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential | Q24656131 | ||
| Nuclear ADP-ribosylation reactions in mammalian cells: where are we today and where are we going? | Q24669960 | ||
| Apoptosis-inducing factor mediates poly(ADP-ribose) (PAR) polymer-induced cell death | Q24673503 | ||
| Myocardial ischemic preconditioning in rodents is dependent on poly (ADP-ribose) synthetase. | Q28344959 | ||
| Suppression of poly (ADP-ribose) polymerase activation by 3-aminobenzamide in a rat model of myocardial infarction: long-term morphological and functional consequences | Q28345810 | ||
| Poly(ADP-ribose) polymerase-1-dependent cardiac myocyte cell death during heart failure is mediated by NAD+ depletion and reduced Sir2alpha deacetylase activity | Q28573891 | ||
| NAD(P)H oxidase: role in cardiovascular biology and disease | Q29616102 | ||
| Poly(ADP-ribose): novel functions for an old molecule | Q29617735 | ||
| Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor | Q29619105 | ||
| Cardiac peroxynitrite formation and left ventricular dysfunction following doxorubicin treatment in mice. | Q31399901 | ||
| Peroxynitrite induced nitration and inactivation of myofibrillar creatine kinase in experimental heart failure | Q32077774 | ||
| Activation of poly(ADP-ribose) polymerase contributes to the endothelial dysfunction associated with hypertension and aging. | Q43994462 | ||
| Immunocytochemical evidence for inducible nitric oxide synthase and cyclooxygenase-2 expression with nitrotyrosine formation in human hibernating myocardium | Q44117815 | ||
| Pharmacologic inhibition of poly(adenosine diphosphate-ribose) polymerase may represent a novel therapeutic approach in chronic heart failure | Q44133546 | ||
| Poly(ADP-Ribose) polymerase is activated in subjects at risk of developing type 2 diabetes and is associated with impaired vascular reactivity | Q44220798 | ||
| Role of poly(ADP-ribose) polymerase activation in endotoxin-induced cardiac collapse in rodents | Q44225537 | ||
| Nitrotyrosine and 8-isoprostane formation indicate free radical-mediated injury in hearts of patients subjected to cardioplegia | Q44285674 | ||
| Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction | Q44319426 | ||
| Beneficial effects of poly (ADP-ribose) polymerase inhibition against the reperfusion injury in heart transplantation | Q44398907 | ||
| Decrease of the inflammatory response and induction of the Akt/protein kinase B pathway by poly-(ADP-ribose) polymerase 1 inhibitor in endotoxin-induced septic shock. | Q44403217 | ||
| Interactions of angiotensin II with NAD(P)H oxidase, oxidant stress and cardiovascular disease | Q44477930 | ||
| Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma | Q44653322 | ||
| The discovery and synthesis of novel adenosine substituted 2,3-dihydro-1H-isoindol-1-ones: potent inhibitors of poly(ADP-ribose) polymerase-1 (PARP-1). | Q44698601 | ||
| Matrix metalloproteinase activation is an early event in doxorubicin-induced cardiotoxicity | Q44725738 | ||
| Poly(ADP-ribose) polymerase contributes to the development of myocardial infarction in diabetic rats and regulates the nuclear translocation of apoptosis-inducing factor | Q44822122 | ||
| Role of poly(ADP-ribose) polymerase activation in the pathogenesis of cardiopulmonary dysfunction in a canine model of cardiopulmonary bypass | Q44843221 | ||
| INO-1001 a novel poly(ADP-ribose) polymerase (PARP) inhibitor improves cardiac and pulmonary function after crystalloid cardioplegia and extracorporal circulation. | Q44846989 | ||
| Poly(ADP-ribose) polymerase inhibitors counteract diabetes- and hypoxia-induced retinal vascular endothelial growth factor overexpression. | Q44940264 | ||
| Restoration of the endothelial function in the aortic rings of apolipoprotein E deficient mice by pharmacological inhibition of the nuclear enzyme poly(ADP-ribose) polymerase | Q44953535 | ||
| The protective effect of superoxide dismutase mimetic M40401 on balloon injury-related neointima formation: role of the lectin-like oxidized low-density lipoprotein receptor-1. | Q44954128 | ||
| 3-Aminobenzamide, an inhibitor of poly (ADP-ribose) synthetase, improves hemodynamics and prolongs survival in a porcine model of hemorrhagic shock | Q45051387 | ||
| Activator protein-1 signalling pathway and apoptosis are modulated by poly(ADP-ribose) polymerase-1 in experimental colitis | Q45156881 | ||
| Poly(ADP-ribose) polymerase inhibition attenuates biventricular reperfusion injury after orthotopic heart transplantation | Q45251195 | ||
| Poly(ADP-ribose) polymerase-1 hyperactivation and impairment of mitochondrial respiratory chain complex I function in reperfused mouse hearts | Q46216917 | ||
| Inhibition of poly(ADP-ribose) polymerase prevents vascular hyporesponsiveness induced by lipopolysaccharide in isolated rat aorta | Q46436975 | ||
| Discovery of potent poly(ADP-ribose) polymerase-1 inhibitors from the modification of indeno[1,2-c]isoquinolinone | Q46633259 | ||
| Poly (ADP) ribose polymerase inhibition improves rat cardiac allograft survival | Q46669171 | ||
| Potential role of poly(adenosine 5'-diphosphate-ribose) polymerase activation in the pathogenesis of myocardial contractile dysfunction associated with human septic shock | Q46950042 | ||
| Poly(ADP-ribose) polymerase inhibition reduces atherosclerotic plaque size and promotes factors of plaque stability in apolipoprotein E-deficient mice: effects on macrophage recruitment, nuclear factor-kappaB nuclear translocation, and foam cell dea | Q47292498 | ||
| Genetic disruption of poly (ADP-ribose) synthetase inhibits the expression of P-selectin and intercellular adhesion molecule-1 in myocardial ischemia/reperfusion injury | Q47817404 | ||
| Inducible nitric oxide synthase expression in smooth muscle cells and macrophages of human transplant coronary artery disease. | Q47930127 | ||
| PARP inhibition prevents postinfarction myocardial remodeling and heart failure via the protein kinase C/glycogen synthase kinase-3beta pathway. | Q48528802 | ||
| Role of nitrosative stress and activation of poly(ADP-ribose) polymerase-1 in cardiovascular failure associated with septic and hemorrhagic shock. | Q51218199 | ||
| Stent-induced neutrophil activation is associated with an oxidative burst in the inflammatory process, leading to neointimal thickening. | Q51245961 | ||
| Effect of genetic disruption of poly (ADP-ribose) synthetase on delayed production of inflammatory mediators and delayed necrosis during myocardial ischemia-reperfusion injury. | Q52537722 | ||
| Compressing drug development timelines in oncology using phase '0' trials. | Q53208031 | ||
| Role of oxidative and nitrosative stress, longevity genes and poly(ADP-ribose) polymerase in cardiovascular dysfunction associated with aging. | Q53850917 | ||
| Role of oxidative-nitrosative stress and downstream pathways in various forms of cardiomyopathy and heart failure. | Q55663138 | ||
| A key role for poly(ADP-ribose) polymerase-1 activity during human dendritic cell maturation | Q61268478 | ||
| Poly(ADP-Ribose) Polymerase Promotes Cardiac Remodeling, Contractile Failure, and Translocation of Apoptosis-Inducing Factor in a Murine Experimental Model of Aortic Banding and Heart Failure | Q61456114 | ||
| Protection against myocardial ischemia and reperfusion injury by 3-aminobenzamide, an inhibitor of poly (ADP-ribose) synthetase | Q61456117 | ||
| Contribution of ATP to oxidative stress-induced changes in action potential of isolated cardiac myocytes | Q73316795 | ||
| Extensive tyrosine nitration in human myocardial inflammation: evidence for the presence of peroxynitrite | Q73425760 | ||
| BGP-15, a nicotinic amidoxime derivate protecting heart from ischemia reperfusion injury through modulation of poly(ADP-ribose) polymerase | Q73487675 | ||
| Apoptosis and increased expression of inducible nitric oxide synthase in human allograft rejection | Q74432629 | ||
| Protection against hypoxia-reoxygenation in the absence of poly (ADP-ribose) synthetase in isolated working hearts | Q74596199 | ||
| Potential role of the peroxynitrate-poly(ADP-ribose) synthetase pathway in a rat model of severe hemorrhagic shock | Q74624318 | ||
| The role of poly(ADP-ribose) polymerase activation in the development of myocardial and endothelial dysfunction in diabetes | Q77550010 | ||
| Reduction of myocardial reperfusion injury by an inhibitor of poly (ADP-ribose) synthetase in the pig | Q77614308 | ||
| Modulation of serum growth factor signal transduction in Hepa 1-6 cells by acetaminophen: an inhibition of c-myc expression, NF-kappaB activation, and Raf-1 kinase activity | Q77826914 | ||
| Possible role of poly(ADP-ribose) polymerase in pathological and physiological cardiac hypertrophy | Q79603264 | ||
| Immunomodulatory effects of poly(ADP-ribose) polymerase inhibition contribute to improved cardiac function and survival during acute cardiac rejection | Q79832890 | ||
| Structure and function of poly(ADP-ribose) polymerase-1: role in oxidative stress-related pathologies | Q80387792 | ||
| Role of nitrosative stress and poly(ADP-ribose) polymerase activation in myocardial reperfusion injury | Q80387796 | ||
| Oxidative-nitrosative stress in hypertension | Q80387798 | ||
| Role of nitrosative stress and poly(ADP-ribose) polymerase activation in diabetic vascular dysfunction | Q80387802 | ||
| Novel roles of nitric oxide in hemorrhagic shock | Q33723158 | ||
| Resistance to endotoxic shock as a consequence of defective NF-kappaB activation in poly (ADP-ribose) polymerase-1 deficient mice | Q33891214 | ||
| Clinical perspectives of PARP inhibitors | Q33987310 | ||
| Poly(ADP-ribose) polymerase-1 dependence of stress-induced transcription factors and associated gene expression in glia | Q34017468 | ||
| Oxidative stress as a signaling mechanism of the vascular response to injury: the redox hypothesis of restenosis | Q34017474 | ||
| Elevated levels of oxidative DNA damage and DNA repair enzymes in human atherosclerotic plaques | Q34145177 | ||
| Absence of poly(ADP-ribose)polymerase-1 alters nuclear factor-kappa B activation and gene expression of apoptosis regulators after reperfusion injury | Q34520738 | ||
| Angiotensin II-mediated endothelial dysfunction: role of poly(ADP-ribose) polymerase activation | Q34521265 | ||
| The therapeutic potential of poly(ADP-ribose) polymerase inhibitors | Q34838585 | ||
| Protein nitration in cardiovascular diseases | Q34995532 | ||
| Intracellular distribution of peroxynitrite during doxorubicin cardiomyopathy: evidence for selective impairment of myofibrillar creatine kinase | Q35044069 | ||
| Endothelial dysfunction in aging animals: the role of poly(ADP-ribose) polymerase activation | Q35044253 | ||
| Nitric oxide, superoxide, and peroxynitrite in myocardial ischaemia-reperfusion injury and preconditioning | Q35044978 | ||
| Poly(ADP-ribose) polymerase inhibitors | Q35060963 | ||
| Multiple pathways of peroxynitrite cytotoxicity | Q35099313 | ||
| Peroxynitrite-induced cytotoxicity: mechanism and opportunities for intervention | Q35099318 | ||
| Activation of the poly(ADP-ribose) polymerase pathway in human heart failure. | Q35113704 | ||
| Activation of poly(ADP)-ribose polymerase (PARP-1) induces release of the pro-inflammatory mediator HMGB1 from the nucleus | Q35120057 | ||
| An inhibitor of poly (ADP-ribose) synthetase activity reduces contractile dysfunction and preserves high energy phosphate levels during reperfusion of the ischaemic rat heart | Q35566493 | ||
| Activation of poly(ADP-ribose) polymerase by myocardial ischemia and coronary reperfusion in human circulating leukocytes | Q35586887 | ||
| Poly(ADP-ribose)polymerase inhibition decreases angiogenesis | Q35676514 | ||
| Pharmacological inhibition of poly(ADP-ribose) polymerase inhibits angiogenesis | Q35676519 | ||
| Poly(ADP-ribose) (PAR) polymer is a death signal | Q35722332 | ||
| Deadly conversations: nuclear-mitochondrial cross-talk | Q35891836 | ||
| Myocardial postischemic injury is reduced by polyADPripose polymerase-1 gene disruption | Q35943974 | ||
| Inhibition of the activity of poly(ADP ribose) synthetase reduces ischemia-reperfusion injury in the heart and skeletal muscle | Q35960752 | ||
| The sirtuin inhibitor nicotinamide enhances neuronal cell survival during acute anoxic injury through AKT, BAD, PARP, and mitochondrial associated "anti-apoptotic" pathways | Q36002884 | ||
| Nitric oxide, peroxynitrite and lipoxygenase in atherogenesis: mechanistic insights | Q36030007 | ||
| Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors | Q36111918 | ||
| Chemopotentiation by PARP inhibitors in cancer therapy. | Q36136079 | ||
| Cardioprotective effects of poly(ADP-ribose) polymerase inhibition | Q36136085 | ||
| Roles of poly(ADP-ribose) polymerase activation in the pathogenesis of diabetes mellitus and its complications | Q36136094 | ||
| Nitrosative stress and pharmacological modulation of heart failure | Q36145124 | ||
| Poly(ADP-ribose) polymerase activation by reactive nitrogen species--relevance for the pathogenesis of inflammation | Q36235834 | ||
| Targeting poly(ADP-ribosyl)ation: a promising approach in cancer therapy | Q36254318 | ||
| Poly(ADP-ribose)polymerase inhibition - where now? | Q36266298 | ||
| Role of poly(ADP-ribose) polymerase-1 activation in the pathogenesis of diabetic complications: endothelial dysfunction, as a common underlying theme | Q36342643 | ||
| Role of peroxynitrite in the pathogenesis of cardiovascular complications of diabetes | Q36398989 | ||
| Novel modulators of poly(ADP-ribose) polymerase | Q36431798 | ||
| Peroxynitrite is a major trigger of cardiomyocyte apoptosis in vitro and in vivo | Q36431848 | ||
| Beneficial effects of a novel ultrapotent poly(ADP-ribose) polymerase inhibitor in murine models of heart failure. | Q36464461 | ||
| Inhibition of poly(ADP-ribose) polymerase in cancer | Q36497225 | ||
| Intracellular targets of matrix metalloproteinase-2 in cardiac disease: rationale and therapeutic approaches | Q36665320 | ||
| Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology | Q36749057 | ||
| Poly (ADP-ribose) polymerase activation and circulatory shock. | Q36767909 | ||
| PARP inhibitors and heart failure--translational medicine caught in the act. | Q36773354 | ||
| Inhibition of poly(adenosine diphosphate-ribose) polymerase by the active form of vitamin D | Q36808300 | ||
| A new, potent poly(ADP-ribose) polymerase inhibitor improves cardiac and vascular dysfunction associated with advanced aging | Q36857395 | ||
| Single dose treatment with PARP-inhibitor INO-1001 improves aging-associated cardiac and vascular dysfunction | Q37198120 | ||
| Endothelial dysfunction in a rat model of endotoxic shock. Importance of the activation of poly (ADP-ribose) synthetase by peroxynitrite | Q37370840 | ||
| Left ventricular pressure-volume relationship in a rat model of advanced aging-associated heart failure | Q37373692 | ||
| Poly(ADP-ribose) polymerase regulates myocardial calcium handling in doxorubicin-induced heart failure | Q37373704 | ||
| Protection against hemorrhagic shock in mice genetically deficient in poly(ADP-ribose)polymerase | Q37429030 | ||
| Modulation of leukocyte-mediated myocardial reperfusion injury | Q37918910 | ||
| Differential regulation of activator protein-1 and heat shock factor-1 in myocardial ischemia and reperfusion injury: role of poly(ADP-ribose) polymerase-1. | Q38346928 | ||
| Novel NAD(P)H oxidase inhibitor suppresses angioplasty-induced superoxide and neointimal hyperplasia of rat carotid artery | Q39643032 | ||
| Spatial and functional relationship between poly(ADP-ribose) polymerase-1 and poly(ADP-ribose) glycohydrolase in the brain | Q40104867 | ||
| INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase, enhances tumor response to doxorubicin | Q40107480 | ||
| ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models | Q40138516 | ||
| Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial. | Q40158513 | ||
| Protective effects of the PARP-1 inhibitor PJ34 in hypoxic-reoxygenated cardiomyoblasts | Q40203725 | ||
| Poly(ADP-ribose) polymerase-1 signaling to mitochondria in necrotic cell death requires RIP1/TRAF2-mediated JNK1 activation | Q40323235 | ||
| Inhibitors of poly (ADP-ribose) synthetase protect rat cardiomyocytes against oxidant stress | Q40954699 | ||
| Protection by inhibition of poly (ADP-ribose) synthetase against oxidant injury in cardiac myoblasts In vitro | Q41090734 | ||
| Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation | Q42497877 | ||
| Two small enzyme isoforms mediate mammalian mitochondrial poly(ADP-ribose) glycohydrolase (PARG) activity. | Q42612100 | ||
| Inhibitors of the activity of poly (ADP-ribose) synthetase reduce the cell death caused by hydrogen peroxide in human cardiac myoblasts | Q43185132 | ||
| Effect of poly(ADP-ribose) polymerase inhibitors on the ischemia-reperfusion-induced oxidative cell damage and mitochondrial metabolism in Langendorff heart perfusion system. | Q43608484 | ||
| Oxidative stress-mediated cardiac cell death is a major determinant of ventricular dysfunction and failure in dog dilated cardiomyopathy | Q43696104 | ||
| Increased inducible nitric oxide synthase expression contributes to myocardial dysfunction and higher mortality after myocardial infarction in mice. | Q43698886 | ||
| Peroxynitrite formation from human myocardium after ischemia-reperfusion during open heart operation | Q43714815 | ||
| Rapid reversal of the diabetic endothelial dysfunction by pharmacological inhibition of poly(ADP-ribose) polymerase | Q43764637 | ||
| 5-aminoisoquinolinone, a potent inhibitor of poly (adenosine 5'-diphosphate ribose) polymerase, reduces myocardial infarct size | Q43791925 | ||
| Poly(ADP-Ribose) polymerase inhibition reduces reperfusion injury after heart transplantation | Q43851360 | ||
| Myocardial protection by PJ34, a novel potent poly (ADP-ribose) synthetase inhibitor | Q43886869 | ||
| Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure | Q43893501 | ||
| Resistance to acute septic peritonitis in poly(ADP-ribose) polymerase-1-deficient mice | Q43960156 | ||
| Poly(ADP-ribose) polymerase activation and cell injury in the course of rat heart heterotopic transplantation. | Q43985830 | ||
| Novel phenanthridinone inhibitors of poly (adenosine 5'-diphosphate-ribose) synthetase: potent cytoprotective and antishock agents | Q43990309 | ||
| P433 | issue | 3 | |
| P921 | main subject | cardiovascular disease | Q389735 |
| P304 | page(s) | 235-260 | |
| P577 | publication date | 2007-01-01 | |
| P1433 | published in | Cardiovascular Drug Reviews | Q13455172 |
| P1476 | title | Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors | |
| P478 | volume | 25 |
| Q38750106 | 1,25(OH)2 D3 improves cardiac dysfunction, hypertrophy, and fibrosis through PARP1/SIRT1/mTOR-related mechanisms in type 1 diabetes. |
| Q92591248 | 25-Hydroxycholesterol protects against myocardial ischemia-reperfusion injury via inhibiting PARP activity |
| Q33930671 | A deficiency of apoptosis inducing factor (AIF) in Harlequin mouse heart mitochondria paradoxically reduces ROS generation during ischemia-reperfusion |
| Q28504824 | ADP-ribosyl-acceptor hydrolase 3 regulates poly (ADP-ribose) degradation and cell death during oxidative stress |
| Q64106175 | ADP-ribosylation signalling and human disease |
| Q53828950 | Antagonistic crosstalk between SIRT1, PARP-1, and -2 in the regulation of chronic inflammation associated with aging and metabolic diseases. |
| Q34049210 | Antiapoptotic effects of Phe140Asn, a novel human granulocyte colony-stimulating factor mutant in H9c2 rat cardiomyocytes |
| Q53832623 | Association of Methylation Signals With Incident Coronary Heart Disease in an Epigenome-Wide Assessment of Circulating Tumor Necrosis Factor α. |
| Q54528429 | BGP-15, a PARP-inhibitor, prevents imatinib-induced cardiotoxicity by activating Akt and suppressing JNK and p38 MAP kinases. |
| Q37781413 | Bench-to-bedside review: Glucose and stress conditions in the intensive care unit |
| Q38089268 | Beyond DNA repair, the immunological role of PARP-1 and its siblings. |
| Q41241222 | CD38 promotes angiotensin II-induced cardiac hypertrophy. |
| Q92855414 | Can Epigenetics of Endothelial Dysfunction Represent the Key to Precision Medicine in Type 2 Diabetes Mellitus? |
| Q35032636 | Cardiac function and disease: emerging role of small ubiquitin-related modifier |
| Q36197657 | Caspase-Dependent and Caspase-Independent Pathways Are Involved in Cadmium-Induced Apoptosis in Primary Rat Proximal Tubular Cell Culture |
| Q41393165 | Comparative study of the binding characteristics to and inhibitory potencies towards PARP and in vivo antidiabetogenic potencies of taurine, 3-aminobenzamide and nicotinamide |
| Q35043866 | Complement dependency of cardiomyocyte release of mediators during sepsis |
| Q35287136 | Cordycepin blocks lung injury-associated inflammation and promotes BRCA1-deficient breast cancer cell killing by effectively inhibiting PARP. |
| Q92618483 | Cul4a as a New Interaction Protein of PARP1 Inhibits Oxidative Stress-Induced H9c2 Cell Apoptosis |
| Q27001756 | DNA damage and repair in atherosclerosis: current insights and future perspectives |
| Q64066898 | DNA damage-induced PARP1 activation confers cardiomyocyte dysfunction through NAD depletion in experimental atrial fibrillation |
| Q33430844 | Developing novel approaches to improve binding energy estimation and virtual screening: a PARP case study |
| Q36237705 | Doxorubicin-induced necrosis is mediated by poly-(ADP-ribose) polymerase 1 (PARP1) but is independent of p53. |
| Q36339445 | Drug-induced mitochondrial dysfunction and cardiotoxicity |
| Q58581240 | Dual Inhibitors of PARPs and ROCKs |
| Q41887087 | Effect and mechanism of poly (ADP-ribose) polymerase-1 in aldosterone-induced apoptosis |
| Q37645201 | Emerging treatment options in the management of non-small cell lung cancer. |
| Q42733136 | Endothelial Nrf2 activation: a new target for resveratrol? |
| Q30408769 | Essential versus accessory aspects of cell death: recommendations of the NCCD 2015. |
| Q88948792 | Examination of Diazaspiro Cores as Piperazine Bioisosteres in the Olaparib Framework Shows Reduced DNA Damage and Cytotoxicity |
| Q35103679 | Fermented wheat germ extract (avemar) in the treatment of cardiac remodeling and metabolic symptoms in rats |
| Q90347654 | Getting an Early Start in Understanding Perinatal Asphyxia Impact on the Cardiovascular System |
| Q88348467 | Improved Reperfusion and Vasculoprotection by the Poly(ADP-Ribose)Polymerase Inhibitor PJ34 After Stroke and Thrombolysis in Mice |
| Q57160461 | Increased ROS production and DNA damage in monocytes are biomarkers of aging and atherosclerosis |
| Q36956379 | Inflammation and endothelial dysfunction during aging: role of NF-kappaB |
| Q37373723 | Inhibition of matrix metalloproteinase-2 by PARP inhibitors |
| Q34731311 | Inhibition of poly (ADP-ribose) polymerase and inducible nitric oxide synthase protects against ischemic myocardial damage by reduction of apoptosis |
| Q30245541 | Investigating Prevalence and Pattern of Long-term Cardiovascular Disorders in Sulphur Mustard-exposed Victims and Determining Proper Biomarkers for Early Defining, Monitoring and Analysis of Patients' Feedback on Therapy |
| Q38728894 | Kynurenine Pathway Metabolism is Involved in the Maintenance of the Intracellular NAD Concentration in Human Primary Astrocytes |
| Q35582672 | Low shear stress induced HMGB1 translocation and release via PECAM-1/PARP-1 pathway to induce inflammation response |
| Q38326656 | Mechanisms of myocardial ischemia-reperfusion injury and the cytoprotective role of minocycline: scope and limitations |
| Q36930481 | Metabolic dysfunction in diabetic cardiomyopathy |
| Q38125279 | Molecular biology of atherosclerosis |
| Q99237973 | NAD+ Metabolism as an Emerging Therapeutic Target for Cardiovascular Diseases Associated With Sudden Cardiac Death |
| Q37879605 | Necrotic cell death in atherosclerosis. |
| Q28486776 | New approaches of PARP-1 inhibitors in human lung cancer cells and cancer stem-like cells by some selected anthraquinone-derived small molecules |
| Q34042969 | New facets in the regulation of gene expression by ADP-ribosylation and poly(ADP-ribose) polymerases |
| Q38020082 | New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs |
| Q38671402 | Nicotinamide mononucleotide requires SIRT3 to improve cardiac function and bioenergetics in a Friedreich's ataxia cardiomyopathy model |
| Q37990715 | On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1. |
| Q35176333 | Opposing roles of PARP-1 in MMP-9 and TIMP-2 expression and mast cell degranulation in dyslipidemic dilated cardiomyopathy |
| Q48280549 | Organ-protective effects on the liver and kidney by minocycline in small piglets undergoing cardiopulonary bypass |
| Q46011485 | PARP inhibition delays transition of hypertensive cardiopathy to heart failure in spontaneously hypertensive rats. |
| Q29619617 | PARP inhibition: PARP1 and beyond |
| Q38326336 | PARP inhibitors |
| Q37829771 | PARP inhibitors and epithelial ovarian cancer: an approach to targeted chemotherapy and personalised medicine. |
| Q35148141 | PARP-1 deficiency blocks IL-5 expression through calpain-dependent degradation of STAT-6 in a murine asthma model |
| Q42442272 | PARP-1 suppresses adiponectin expression through poly(ADP-ribosyl)ation of PPAR gamma in cardiac fibroblasts |
| Q30434858 | PARP-inhibitor treatment prevents hypertension induced cardiac remodeling by favorable modulation of heat shock proteins, Akt-1/GSK-3β and several PKC isoforms |
| Q37293979 | PARP1 inhibition affects pleural mesothelioma cell viability and uncouples AKT/mTOR axis via SIRT1. |
| Q57461771 | PARP1 promote autophagy in cardiomyocytes via modulating FoxO3a transcription |
| Q61688083 | PARylation, DNA (De)methylation, and Diabetes |
| Q38200674 | Parthanatos: mitochondrial-linked mechanisms and therapeutic opportunities |
| Q28080057 | Pathophysiological Role of Peroxynitrite Induced DNA Damage in Human Diseases: A Special Focus on Poly(ADP-ribose) Polymerase (PARP) |
| Q38876257 | Pathways of cardiac toxicity: comparison between chemotherapeutic drugs doxorubicin and mitoxantrone. |
| Q58777359 | Poly (ADP-Ribose) Polymerase 1 Mediated Arginase II Activation Is Responsible for Oxidized LDL-Induced Endothelial Dysfunction |
| Q37750189 | Poly ADP-ribose polymerase-1 and health |
| Q41820940 | Poly(ADP-Ribose)Polymerase-1 in Lung Inflammatory Disorders: A Review. |
| Q36987659 | Poly(ADP-ribose) Polymerase 1 Represses Liver X Receptor-mediated ABCA1 Expression and Cholesterol Efflux in Macrophages |
| Q37735746 | Poly(ADP-ribose) metabolism in brain and its role in ischemia pathology |
| Q64099179 | Poly(ADP-ribose) polymerase 1 accelerates vascular calcification by upregulating Runx2 |
| Q33669053 | Poly(ADP-ribose) polymerase inhibitors in triple-negative breast cancer |
| Q37773040 | Poly(ADP-ribose) polymerase-1 (PARP-1) and its therapeutic implications |
| Q34441033 | Poly(ADP-ribose) polymerase-1 (PARP-1) gene deficiency alleviates diabetic kidney disease. |
| Q38137764 | Predictive biomarkers for cancer therapy with PARP inhibitors. |
| Q39242312 | Pretreatment of therapeutic cells with poly(ADP-ribose) polymerase inhibitor enhances their efficacy in an in vitro model of cell-based therapy in myocardial infarct |
| Q37181486 | Promotion of cellular NAD(+) anabolism: therapeutic potential for oxidative stress in ageing and Alzheimer's disease. |
| Q33510142 | Protective effects of PARP-1 knockout on dyslipidemia-induced autonomic and vascular dysfunction in ApoE mice: effects on eNOS and oxidative stress |
| Q37267855 | Protein kinase C protects from DNA damage-induced necrotic cell death by inhibiting poly(ADP-ribose) polymerase-1 |
| Q34650147 | Reduced estradiol-induced vasodilation and poly-(ADP-ribose) polymerase (PARP) activity in the aortas of rats with experimental polycystic ovary syndrome (PCOS). |
| Q34390683 | Regulatory role of mitochondria in oxidative stress and atherosclerosis |
| Q34787965 | Resveratrol attenuates azidothymidine-induced cardiotoxicity by decreasing mitochondrial reactive oxygen species generation in human cardiomyocytes |
| Q37230827 | Role of nitrosative stress in the pathogenesis of diabetic vascular dysfunction |
| Q37181684 | Role of poly(ADP-ribosyl)ation in a 'two-hit' model of hypoxia and oxidative stress in human A549 epithelial cells in vitro |
| Q37200311 | Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro |
| Q36734840 | Role of the peroxynitrite-poly(ADP-ribose) polymerase pathway in human disease |
| Q28076837 | SIRT3 in Cardiac Physiology and Disease |
| Q90090945 | SIRT3 inhibits cardiac hypertrophy by regulating PARP-1 activity |
| Q52592887 | SIRT3: A New Regulator of Cardiovascular Diseases. |
| Q90092097 | Selective targeting of ubiquitination and degradation of PARP1 by E3 ubiquitin ligase WWP2 regulates isoproterenol-induced cardiac remodeling |
| Q37239817 | Sepsis: links between pathogen sensing and organ damage |
| Q64052985 | Signal-induced PARP1-Erk synergism mediates IEG expression |
| Q57822214 | Sirtuins and NAD in the Development and Treatment of Metabolic and Cardiovascular Diseases |
| Q27004584 | Structure and function of the ARH family of ADP-ribosyl-acceptor hydrolases |
| Q58605028 | Synthesis and evaluation of an AZD2461 [F]PET probe in non-human primates reveals the PARP-1 inhibitor to be non-blood-brain barrier penetrant |
| Q34204660 | Targeting poly(ADP-ribose) polymerase activity for cancer therapy |
| Q24606586 | The DNA-damage response in human biology and disease |
| Q57816662 | The MacroH2A1.1 - PARP1 Axis at the Intersection Between Stress Response and Metabolism |
| Q37770152 | The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets |
| Q34443624 | The biochemical pathways of central nervous system neural degeneration in niacin deficiency |
| Q37118012 | The importance of NAD in multiple sclerosis |
| Q28581148 | The orphan receptor NOR1 participates in isoprenaline-induced cardiac hypertrophy by regulating PARP-1 |
| Q38554517 | The role of DNA damage and repair in atherosclerosis: A review. |
| Q36853236 | Therapeutic applications of PARP inhibitors: anticancer therapy and beyond |
| Q46494229 | Toxicity of lithium on isolated heart mitochondria and cardiomyocyte: A justification for its cardiotoxic adverse effect |
| Q33799832 | Trypanosoma cruzi induces the reactive oxygen species-PARP-1-RelA pathway for up-regulation of cytokine expression in cardiomyocytes |
| Q50277380 | Vascular endothelial growth factor confers endothelial resistance to apoptosis through poly(ADP-ribose) polymerase. |
| Q33832010 | Vincristine attenuates N-methyl-N'-nitro-N-nitrosoguanidine-induced poly-(ADP) ribose polymerase activity in cardiomyocytes |
Search more.